Allogeneic Human MEsenchymal Stem Cell (MSC) Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Hypoplastic left heart syndrome
- Focus Adverse reactions
- Acronyms ELPIS
- Sponsors Longeveron
- 07 Nov 2019 Planned End Date changed from 1 Feb 2022 to 1 Mar 2021.
- 07 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 18 May 2018 New trial record